Related Experiment Videos
[A malignant extra-adrenal pheochromocytoma. Apropos 2 cases]
C Cuerda1, I Castejón, B Astigarraga
1Servicio de Endocrinología, Clínica Puerta de Hierro, Madrid.
Revista Clinica Espanola
|February 1, 1993
Summary
Metaiodobenzylguanidine-I-123 (MIBG-I-123) scans detected unexpected skull bone metastasis in two patients with extra-adrenal pheochromocytoma. Surgical resection of both the primary tumor and bone lesions proved effective.
Area of Science:
- Endocrinology
- Oncology
- Nuclear Medicine
Background:
- Extra-adrenal pheochromocytoma is a rare neuroendocrine tumor.
- Malignant pheochromocytoma can metastasize, posing diagnostic and therapeutic challenges.
- Accurate staging is crucial for effective treatment planning.
Observation:
- Two patients with extra-adrenal pheochromocytoma presented with previously unsuspected bone metastasis.
- Metaiodobenzylguanidine-I-123 (MIBG-I-123) scintigraphy identified metastatic lesions in the skullcap.
- These metastases were not detected by initial pre-surgical evaluations.
Findings:
- MIBG-I-123 is highly effective in localizing metastatic disease in malignant pheochromocytoma.
- Surgical resection of both the primary tumor and isolated bone metastases was successfully performed in both cases.
- Complete tumor removal is a viable treatment strategy for pheochromocytoma with limited metastatic spread.
Implications:
- This study highlights the critical role of MIBG-I-123 in detecting occult bone metastases from pheochromocytoma.
- Aggressive surgical management of localized metastatic disease can lead to favorable outcomes.
- Early and accurate diagnosis through advanced imaging is essential for improving patient survival in malignant pheochromocytoma.